AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

AbbVie (ABBV) announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations in the third quarter. AbbVie is set to report its third-quarter results on Oct. 30.The adjusted earnings guidance for 2024 was lowered from $10.71-$10.91 per share to $10.67 - $10.87 to account for acquisition costs of $82 million on ...